Skip to main content
Erschienen in: Reactions Weekly 1/2021

01.01.2021 | Case report

Adalimumab/etanercept/infliximab

Treatment failure: case report

Erschienen in: Reactions Weekly | Ausgabe 1/2021

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Chaparro Sanabria JA, et al. Treatment of uveitis and ankylosing spondylitis refractory to three tumor necrosis factor alpha inhibitors drugs with golimumab. Reumatologia Clinica 16: 64-65, No. 1, Jan-Feb 2020. Available from: URL: http://doi.org/10.1016/j.reuma.2018.01.003 [Italian; summarised from a translation] Chaparro Sanabria JA, et al. Treatment of uveitis and ankylosing spondylitis refractory to three tumor necrosis factor alpha inhibitors drugs with golimumab. Reumatologia Clinica 16: 64-65, No. 1, Jan-Feb 2020. Available from: URL: http://​doi.​org/​10.​1016/​j.​reuma.​2018.​01.​003 [Italian; summarised from a translation]
Metadaten
Titel
Adalimumab/etanercept/infliximab
Treatment failure: case report
Publikationsdatum
01.01.2021
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2021
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-021-90160-4

Weitere Artikel der Ausgabe 1/2021

Reactions Weekly 1/2021 Zur Ausgabe

Case report

Dexamethasone

Case report

Macitentan

Case report

Ciprofloxacin

Case report

Multiple drugs